Accordingly, at the time of MS diagnosis increased CSF levels of proinflammatory molecules, including interleukin (IL)-1β, IL-2, and IL-6, have been associated with higher prospective disease activity and a worse disease course [1,2,3]. The gene discussed is IL2; the disease is myeloid sarcoma.